AVDL vs. COLL, BCYC, BDSI, IMUX, AGLE, SMMT, OGN, BBIO, APLS, and MDGL
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Collegium Pharmaceutical (COLL), Bicycle Therapeutics (BCYC), BioDelivery Sciences International (BDSI), Immunic (IMUX), Aeglea BioTherapeutics (AGLE), Summit Therapeutics (SMMT), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Apellis Pharmaceuticals (APLS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "medical" sector.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
Collegium Pharmaceutical has a net margin of 16.46% compared to Avadel Pharmaceuticals' net margin of -284.42%. Collegium Pharmaceutical's return on equity of 104.98% beat Avadel Pharmaceuticals' return on equity.
Collegium Pharmaceutical received 47 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 65.22% of users gave Collegium Pharmaceutical an outperform vote while only 65.22% of users gave Avadel Pharmaceuticals an outperform vote.
69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 4.0% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Collegium Pharmaceutical has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 3 mentions for Avadel Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 1.07 beat Avadel Pharmaceuticals' score of 0.81 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.
Avadel Pharmaceuticals currently has a consensus price target of $24.17, suggesting a potential upside of 59.73%. Collegium Pharmaceutical has a consensus price target of $40.75, suggesting a potential upside of 22.78%. Given Avadel Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avadel Pharmaceuticals is more favorable than Collegium Pharmaceutical.
Avadel Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
Summary
Collegium Pharmaceutical beats Avadel Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
